Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. The metric has seen a significant loss of -14.41% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -31.40%. Over the past 30 days, the price of GLMD has fallen by 8.34%. And in the last five days, it has surged by 44.07%.
The stock market performance of Galmed Pharmaceuticals Ltd has been fairly unsteady. Over the last year, the company’s stock hit its highest at $23.80 on 09/17/24, while the lowest price during the same time frame was $1.67, recorded on 03/14/25.
52-week price history of GLMD Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Galmed Pharmaceuticals Ltd’s current trading price is -88.53% away from its 52-week high, while its distance from the 52-week low is 63.49%. The stock’s price range over this timeframe has been between $1.67 and $23.80. The shares of the Healthcare sector company recorded a trading volume of approximately 39.96 million for the day, which was comparatively higher than the average daily volume of 32650.0 over the last three months.
The Connection Between Financial Performance and Market Capitalization
Galmed Pharmaceuticals Ltd (GLMD) has experienced a quarterly decline of -5.20% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.52M and boasts a workforce of 8 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.8678, with a change in price of -1.1760. Similarly, Galmed Pharmaceuticals Ltd recorded 418,654 in trading volume during the last 100 days, posting a change of -30.95%.
GLMD’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for GLMD stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
GLMD Stock Stochastic Average
The raw stochastic average for Galmed Pharmaceuticals Ltd over the last 50 days is presently at 49.18%. This reflects a drop from the raw stochastic average of the previous 20 days, which was noted at 52.13%. Further, the company’s Stochastic %K and %D values for the last 20 days were 19.53% and 10.39%, respectively.
